Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 8;39(3):362–369. doi: 10.1097/ICO.0000000000002182

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

FIGURE 3. — Clinical findings after intrastromal injection of 25 μL of BSS or AAV-GFP using either the 31-G or PCI needle in vivo. A, Clinical color images of the injection site. The injection resulted in corneal opacity immediately after injection, which resolved by day 1 after injection (n = 12 injections/group). B, Adverse events during the injection procedure. During the injection, AC perforation (46% vs. 8%) and injection site leakage (100% vs. 46%) were more frequent using the 31-G versus the PCI microneedle. C, Mean cumulative ocular inflammatory scores demonstrate only a mild inflammatory response at 1 day after injection, which resolved completely by day 5.